Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit

AIDS

Volumn 14, Issue 10, 2000, Pages 1383-1388

  Reiss, P ^a   Vella, S ^a   Cooper, D ^a   Lange, J ^a   Gartland, M ^a   Gerstoft, J ^a   Goebel, F ^a   Larder, B ^a   Clumeck, N ^a   Gatell, J ^a   Gazzard, B ^a   Rozenbaum, W ^a   Rae, S ^a   O'Shaughnessy, M V ^a   Robinson, P ^a   Harrigan, P R ^a   Raboud, J ^a   Alexander, C S ^a   Maguire, M ^a   Montaner, J S ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

CD4 cell count; HIV; Protease inhibitor; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; T LYMPHOCYTE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LINEAR MODELS; MULTIVARIATE ANALYSIS; TIME FACTORS; VIREMIA;

EID: 0033941115     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00011     Document Type: Article

References (26)

1. 1. Mellors JW, Rinaldo CR Jr, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
2. 2. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
3. 3. Montaner JS, DeMasi R, Hill AM. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998, 12:F23-F28.
4. 4. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Croup Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
5. 5. Carpenter CC, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. J Am Med Assoc 1998, 280:78-86.
6. 6. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
7. 7. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723-724.
8. 8. Piketty C, Castiel P, Belec L et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.
9. 9. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
10. 10. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 1998, 338:1074.
11. 11. Stoddart C, Mammano F, Moreno M et al. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago. January-February 1999 [abstract 4].
12. 12. Faye A, Race E, Obry V et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 331].
13. 13. Phenix BN, Mandy F, Chambers KA et al. Prevention of HIV associated T cell apoptosis by inhibitors of HIV protease. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 349].
14. 14. Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial, Italy, The Netherlands, Canada and Australia Study. J Am Med Assoc 1998, 279:930-937.
15. 15. Gerstoft J on behalf of the AVANTI Group. AVANTI 2: a randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs. AZT/ 3TC/indinavir in antiretroviral naive patients. 37th International Congress on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-87].
16. 16. Clumeck N for the AVANTI Study Group. AVANTI 3: a randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naïve patients. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998 [abstract 8].
17. 17. Harris M, Patenaude P, Cooperberg P et al. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Croup, Italy, Netherlands, Canada, Australia and United States. J Infect Dis 1997, 176:1388-1392.
18. 18. Raboud JM, Rae S, Hogg RS et dl. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis 1999, 180:1347-1350.
19. 19. Mulder J, Christopherson C, Sninsky J, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type-1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
20. 20. Mulder J, Resnick R, Saget B et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997, 35: 1278-1280.
21. 21. Sun R, Ku J, Jayakar H et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. Clin Microbiol 1998, 36:2964-2969.
22. 22. Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994, 343:871-881.
23. 23. Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 1996, 10(Suppl 5):S11-S19.
24. 24. Pakker NG, Kroon ED, Roos MT et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999, 13:203-212.
25. 25. Hill A, Montaner JS, Lederman M for the CNA3005 Study Group. Discordant CD4/RNA responses to HAART are strongly associated with high baseline CD4 cell count and low HIV RNA: analysis of 406 naive patients. Third International Workshop on Drug Resistance and Treatment Strategies. San Diego, June 1999 [poster 152].
26. 26. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 28:F59-F62.